Latest News

Novozymes bags Organobalance

Enzyme fermentation at Novozymes' pilot plant, in Bagsværd, Denmark © Novozymes


Denmark’s Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology.

Germany-based Organobalance specializes in developing natural microbial solutions for customers and partners across a number of industries including food, feed, and animal health. Now, the company with a staff of 29  has been bought up by Danish industrial enzymes and microorganism expert Novozymes for an undisclosed amount.

“The experience of Organobalance’s founding scientists, and the company’s know-how, immediately strengthen Novozymes’ existing capabilities within microbial technologies,” says Sebastian Søderberg, Vice President for New Business Development, Incubation & Acquisitions at Novozymes. “Organobalance will advance our understanding to develop new, sustainable solutions across industries, and provide us with additional commercial opportunities.”

Organobalance co-founder Christine Lang will continue as General Manager. Lang commented: “By becoming part of Novozymes, we will have access to a global R&D network and an extensive infrastructure to bring products to market – a clear advantage for us and our customers."

Experts discuss link between sepsis and Covid-19

At a virtual conference on sepsis and its relation to Covid-19 held at the University Hospital Charité in Berlin, Niels Riedemann, CEO of Inflarx NV,...

UK researchers present dengue virus transmission map

The map of variation in dengue transmission intensity rather than current maps of endemicity offers clues about the most effective types of...

AMR: IMI’s Enable project reaches endpoints

The IMI project was recently granted a one-year extension to promote further progression of ongoing programmes, while keeping within the original...

North Sea Therapeutics raises US$40m in Series B

Besides the completion of the ongoing Phase 2b ICONA study on icosabutate in safety and efficacy in NASH (Non-alcoholic Steatohepatitis), North Sea...

Hydrogel fights wound infection and inflammation

The new gel mimics the body’s natural defenses to tackle both inflammation and bacterial infection – two major concerns for patients recovering from...

Vitamin C may boost checkpoint inhibitor efficacy

Results obtained from mice models suggest that the vitamin should be tested as a supporting treatment for cancer patients receiving immunotherapies....

Illumina embraces Roche

Just in time for the start of the JP Morgan conference, Roche and Illumina, the competitors in the emerging market of NGS-based cancer patient...